AI assistant
Dermata Therapeutics, Inc. — Director's Dealing 2021
Aug 17, 2021
35467_dirs_2021-08-17_ac83cb8c-f782-4037-9b0f-f51844a17a6e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Dermata Therapeutics, Inc. (DRMA)
CIK: 0001853816
Period of Report: 2021-08-17
Reporting Person: INSLEY THOMAS (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-17 | Common Stock | C | 4581 | — | Acquired | 14337 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-17 | Series 1d Preferred Stock | $ | C | 30910 | Disposed | Common Stock (4581) | Indirect |
Footnotes
F1: The Series 1d Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
F2: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.